Neuropathies in the context of malignancies.

Purpose Of Review: To conduct a critical review of recent data pertaining to the clinical and therapeutic aspects of peripheral neuropathies in the setting of malignancies, with the exception of paraproteinemic neuropathies. Our search extended to the past 2 years, using a PubMed search strategy.

Recent Findings: In the field of neuropathies linked with the development of the cancer, recent works have focused on lymphoma and cancer-associated vasculitides.

[Epidemiological and clinical aspects of CIDP].

The aim of this study is to give a current overview of CIDP. Indeed, since it was first described in 1975, this entity appears to have evolved considerably. Based on an analysis of 146 patients diagnosed with CIDP at the Centre de Référence de Pathologie Neuromusculaire Paris Est between January 2005 and August 2006, our study seeks to answer the following questions: What is the frequency of this neuropathy? What are the diagnostic criteria? What is the clinical spectrum of CIDP? What is the frequency of the various clinical variants? How many CIDP variants are associated with another disease, and with which other diseases? What is the frequency of CIDP associated with a monoclonal gammopathy? What is the range of possible outcomes, and is CIDP a severe disease? Are current treatments for CIDP satisfactory?

[New approaches for the treatment of metabolic myopathies].

Metabolic myopathies are inborn errors of intermediate muscle metabolism, presenting either by exercise intolerance, or by progressive muscle weakness. Growing knowledge concerning the pathophysiology of these rare disorders, and the development of new technologies, opens new avenues for the treatment of this group of myopathies. Recent studies showed improvement in exercise capacity after regular aerobic exercise training in patients with McArdle's disease and mitochondrial myopathies.